Report cover image

U.S. Gene Therapy Market - Industry Outlook & Forecast 2022-2027

Publisher Arizton Advisory and Intelligence
Published Mar 24, 2022
Length 208 Pages
SKU # ARZ17043169

Description

U.S. Gene Therapy Market - Industry Outlook & Forecast 2022-2027

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this U.S. Gene Therapy Market Report

The market is witnessing steady growth due to the increased availability of funding from various public and private institutes. In addition, there is increased support from regulatory bodies for product approvals and providing fast-track designations to the products, which encourages vendors to manufacture the products at a faster rate.

U.S. gene therapy market is expected to grow at a CAGR of 43.44% during 2022-2027

MARKET OPPORTUNITIES AND TRENDS
  • Increasing Market Access for Gene Therapies
  • Introduction Of Universal Car-T Therapy
  • Increase In Strategic Acquisitions
  • Increased Funding For R&D Activities of Gene Therapies
The US gene therapy market would realize an absolute growth of over 771.00% in terms of revenue between 2021 and 2027.

U.S. GENE THERAPY MARKET SEGMENTATION

Among product type segments, the CAR-T therapy segment dominates the US gene therapy market, accounting for a share of 51.96%, followed by non-CAR-T therapy with 48.04% in 2021.

Based on the vector type, the US gene therapy market is segmented into retroviral and others. The other segment includes adeno virus, adeno-associated virus, herpes simplex virus, and non-viral vectors. The retroviral segment accounted for a major share of 51.96% and others with 48.04% in 2021

Based on end-users, the market is segmented into hospitals, cancer care centers, and academic & research centers. The hospital segment dominated the market with a share of 56.45%, followed by cancer care centers with 35.87%.

Market Segmentation by Vector Type
  • Retroviral
  • Others
Market Segmentation by Product Type
  • Car T Therapy
  • Non-Car T Therapy
Market Segmentation by Indication
  • Oncology
  • Others
Market Segmentation by Gene Transfer
  • Ex-Vivo
  • In-Vivo
Market Segmentation by End User
  • Hospitals
  • Cancer Care Centers
  • Academic & Research Centers
VENDOR ANALYSIS

The US gene therapy market is witnessing the high competition among the vendors. The market is characterized by the presence of various pharma and various small-scale companies. With the changing market landscape, the competition is turning intense due to some recent high-value M&As.

Key Vendors
  • Amgen
  • bluebird bio
  • Bristol Myers Squibb
  • Gilead Sciences
  • Novartis
  • F. Hoffmann-La Roche
Other Prominent Vendors
  • 4DMT
  • Abeona Therapeutics
  • AnGes
  • AskBio
  • Astellas Gene Therapies
  • Autolus Therapeutics
  • Candel Therapeutics
  • Castle Creek Biosciences
  • Cellectis
  • Evox Therapeutics
  • Freeline Therapeutics
  • Gene Biotherapeutics
  • Generation Bio
  • GenSight Biologics
  • Helixmith
  • Janssen Pharmaceuticals
  • Kolon Tissue Gene
  • Krystal Biotech
  • MeiraGTx
  • Orchard Therapeutics
  • Pfizer
  • Poseida Therapeutics
  • Passage Bio
  • RegenxBio
  • Sana Biotechnology
  • Sarepta Therapeutics
  • StrideBio
  • Solid Biosciences
  • VBL Therapeutics
  • Voyager Therapeutics
  • Uniqure
THE REPORT INCLUDES:

1. The analysis of the U.S. Gene Therapy market size and growth rate for the forecast period 2022-2027.

2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the U.S. Gene Therapy market.

3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.

4. It offers a complete overview of market segments and the regional outlook of the Gene Therapy market.

5. The report offers a detailed overview of the vendor landscape, competitive analysis, and critical market strategies to gain competitive advantage.

Table of Contents

208 Pages
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY VECTOR
4.3.2 MARKET SEGMENTATION BY PRODUCT
4.3.3 MARKET SEGMENTATION BY INDICATION
4.3.4 MARKET SEGMENTATION BY GENE TRANSFER
4.3.5 MARKET SEGMENTATION BY END-USERS
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 BACKGROUND
7.2 GENE THERAPY: AN OVERVIEW
7.2.1 EVOLUTION OF GENE THERAPY
8 REIMBURSEMENT FOR GENE THERAPY IN US
8.1 OVERVIEW
9 REGULATORY SCENARIO FOR GENE THERAPY PRODUCTS
9.1 OVERVIEW
9.2 CLINICAL TRIAL PROCESS FOR GENE THERAPY
10 COMMERCIAL GENE THERAPY PRODUCTS IN US
10.1 OVERVIEW
10.1.1 ABECMA (IDECABTAGENE VICLEUCEL)
10.1.2 BREYANZI (LISOCABTAGENE MARALEUCEL)
10.1.3 TECARTUS (BREXUCABTAGENE AUTOLEUCEL)
10.1.4 ZOLGENSMA (ONASEMNOGENE ABEPARVOVEC)
10.1.5 LUXTURNA (VORETIGENE NEPARVOVEC)
10.1.6 YESCARTA (AXICABTAGENE CILOLEUCEL)
10.1.7 KYMRIAH (TISAGENLECLEUCEL-T)
10.1.8 IMLYGIC (TALIMOGENE LAHERPAREPVEC)
11 GENE THERAPY PRODUCTS IN PIPELINE
11.1 OVERVIEW
12 MARKET OPPORTUNITIES & TRENDS
12.1 INCREASING MARKET ACCESS FOR GENE THERAPIES
12.2 INTRODUCTION OF UNIVERSAL CAR-T THERAPY
12.3 INCREASE IN STRATEGIC ACQUISITIONS
12.4 INCREASED FUNDING FOR R&D ACTIVITIES OF GENE THERAPIES
13 MARKET GROWTH ENABLERS
13.1 INCREASE IN CMOS TO MANUFACTURE GENE THERAPIES
13.2 INCREASING TARGET PATIENT POPULATION
13.3 PRODUCT LAUNCHES & REGULATORY APPROVALS
13.4 REGULATORY SUPPORT & SPECIAL DESIGNATIONS FOR GENE THERAPIES
14 MARKET RESTRAINTS
14.1 HIGH COST OF GENE THERAPY PRODUCTS
14.2 LIMITATIONS OF GENE THERAPY PRODUCTS
14.3 AVAILABILITY OF ALTERNATIVE THERAPEUTICS & WITHDRAWAL OF PRODUCTS
15 MARKET LANDSCAPE
15.1 MARKET OVERVIEW
15.2 MARKET SIZE & FORECAST
15.2.1 INSIGHTS BY VECTOR TYPE
15.2.2 INSIGHTS BY PRODUCT TYPE
15.2.3 INSIGHTS BY INDICATION TYPE
15.2.4 INSIGHTS BY GENE TRANSFER TYPE
15.2.5 INSIGHTS BY END-USERS
15.3 FIVE FORCES ANALYSIS
15.3.1 THREAT OF NEW ENTRANTS
15.3.2 BARGAINING POWER OF SUPPLIERS
15.3.3 BARGAINING POWER OF BUYERS
15.3.4 THREAT OF SUBSTITUTES
15.3.5 COMPETITIVE RIVALRY
16 VECTOR TYPE
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 RETROVIRAL
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.4 OTHER VECTORS
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
17 PRODUCT TYPE
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 MARKET OVERVIEW
17.3 CAR-T THERAPY
17.3.1 MARKET OVERVIEW
17.3.2 MARKET SIZE & FORECAST
17.4 NON-CAR-T THERAPY
17.4.1 MARKET OVERVIEW
17.4.2 MARKET SIZE & FORECAST
18 INDICATION
18.1 MARKET SNAPSHOT & GROWTH ENGINE
18.2 MARKET OVERVIEW
18.3 ONCOLOGY
18.3.1 MARKET OVERVIEW
18.3.2 MARKET SIZE & FORECAST
18.4 OTHERS
18.4.1 MARKET OVERVIEW
18.4.2 MARKET SIZE & FORECAST
19 GENE TRANSFER
19.1 MARKET SNAPSHOT & GROWTH ENGINE
19.2 MARKET OVERVIEW
19.3 EX-VIVO
19.3.1 MARKET OVERVIEW
19.3.2 MARKET SIZE & FORECAST
19.4 IN-VIVO
19.4.1 MARKET OVERVIEW
19.4.2 MARKET SIZE & FORECAST
20 END-USERS
20.1 MARKET SNAPSHOT & GROWTH ENGINE
20.2 MARKET OVERVIEW
20.3 HOSPITALS
20.3.1 MARKET OVERVIEW
20.3.2 MARKET SIZE & FORECAST
20.4 CANCER CARE CENTERS
20.4.1 MARKET OVERVIEW
20.4.2 MARKET SIZE & FORECAST
20.5 ACADEMIC & RESEARCH CENTERS
20.5.1 MARKET OVERVIEW
20.5.2 MARKET SIZE & FORECAST
21 COMPETITIVE LANDSCAPE
21.1 COMPETITION OVERVIEW
21.2 MARKET SHARE ANALYSIS
21.2.1 AMGEN
21.2.2 BLUEBIRD BIO
21.2.3 BRISTOL MYERS SQUIBB
21.2.4 GILEAD SCIENCES
21.2.5 NOVARTIS
21.2.6 F. HOFFMANN-LA ROCHE
22 KEY COMPANY PROFILES
22.1 AMGEN
22.1.1 BUSINESS OVERVIEW
22.1.2 PRODUCT OFFERINGS
22.1.3 KEY STRATEGIES
22.1.4 KEY STRENGTHS
22.1.5 KEY OPPORTUNITIES
22.2 BLUEBIRD BIO
22.2.1 BUSINESS OVERVIEW
22.2.2 PRODUCT OFFERINGS
22.2.3 KEY STRATEGIES
22.2.4 KEY STRENGTHS
22.2.5 KEY OPPORTUNITIES
22.3 BRISTOL MYERS SQUIBB
22.3.1 BUSINESS OVERVIEW
22.3.2 PRODUCT OFFERINGS
22.3.3 KEY STRATEGIES
22.3.4 KEY STRENGTHS
22.3.5 KEY OPPORTUNITIES
22.4 GILEAD SCIENCES
22.4.1 BUSINESS OVERVIEW
22.4.2 PRODUCT OFFERINGS
22.4.3 KEY STRATEGIES
22.4.4 KEY STRENGTHS
22.4.5 KEY OPPORTUNITIES
22.5 NOVARTIS
22.5.1 BUSINESS OVERVIEW
22.5.2 PRODUCT OFFERINGS
22.5.3 KEY STRATEGIES
22.5.4 KEY STRENGTHS
22.5.5 KEY OPPORTUNITIES
22.6 F. HOFFMANN-LA ROCHE
22.6.1 BUSINESS OVERVIEW
22.6.2 PRODUCT OFFERINGS
22.6.3 KEY STRATEGIES
22.6.4 KEY STRENGTHS
22.6.5 KEY OPPORTUNITIES
23 GENE THERAPY INVESTIGATIONAL COMPANIES
23.1 4DMT
23.1.1 BUSINESS OVERVIEW
23.2 ABEONA THERAPEUTICS
23.2.1 BUSINESS OVERVIEW
23.3 ANGES
23.3.1 BUSINESS OVERVIEW
23.4 ASKBIO
23.4.1 BUSINESS OVERVIEW
23.5 ASTELLAS GENE THERAPIES
23.5.1 BUSINESS OVERVIEW
23.6 AUTOLUS THERAPEUTICS
23.6.1 BUSINESS OVERVIEW
23.7 CANDEL THERAPEUTICS
23.7.1 BUSINESS OVERVIEW
23.8 CASTLE CREEK BIOSCIENCES
23.8.1 BUSINESS OVERVIEW
23.9 CELLECTIS
23.9.1 BUSINESS OVERVIEW
23.10 EVOX THERAPEUTICS
23.10.1 BUSINESS OVERVIEW
23.11 FREELINE THERAPEUTICS
23.11.1 BUSINESS OVERVIEW
23.12 GENE BIOTHERAPEUTICS
23.12.1 BUSINESS OVERVIEW
23.13 GENERATION BIO
23.13.1 BUSINESS OVERVIEW
23.14 GENSIGHT BIOLOGICS
23.14.1 BUSINESS OVERVIEW
23.15 HELIXMITH
23.15.1 BUSINESS OVERVIEW
23.16 JANSSEN PHARMACEUTICALS
23.16.1 BUSINESS OVERVIEW
23.17 KOLON TISSUE GENE
23.17.1 BUSINESS OVERVIEW
23.18 KRYSTAL BIOTECH
23.18.1 BUSINESS OVERVIEW
23.19 MEIRAGTX
23.19.1 BUSINESS OVERVIEW
23.20 ORCHARD THERAPEUTICS
23.20.1 BUSINESS OVERVIEW
23.21 PFIZER
23.21.1 BUSINESS OVERVIEW
23.22 POSEIDA THERAPEUTICS
23.22.1 BUSINESS OVERVIEW
23.23 PASSAGE BIO
23.23.1 BUSINESS OVERVIEW
23.24 REGENXBIO
23.24.1 BUSINESS OVERVIEW
23.25 SANA BIOTECHNOLOGY
23.25.1 BUSINESS OVERVIEW
23.26 SAREPTA THERAPEUTICS
23.26.1 BUSINESS OVERVIEW
23.27 STRIDEBIO
23.27.1 BUSINESS OVERVIEW
23.28 SOLID BIOSCIENCES
23.28.1 BUSINESS OVERVIEW
23.29 VBL THERAPEUTICS
23.29.1 BUSINESS OVERVIEW
23.30 VOYAGER THERAPEUTICS
23.30.1 BUSINESS OVERVIEW
23.31 UNIQURE
23.31.1 BUSINESS OVERVIEW
24 REPORT SUMMARY
24.1 KEY TAKEAWAYS
24.2 STRATEGIC RECOMMENDATIONS
25 QUANTITATIVE SUMMARY
25.1 MARKET BY VECTOR TYPE
25.2 MARKET BY PRODUCT TYPE
25.3 MARKET BY INDICATION
25.4 MARKET BY GENE TRANSFER
25.5 MARKET BY END-USER
26 APPENDIX
26.1 ABBREVIATIONS

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us